$CVS has released new earnings for Q4 2024, showing an EPS of $1.19, surpassing estimates by $0.27, and revenue of $97.71B, up 4.15% Y/Y. Highlights include strong growth in healthcare benefits, but concerns remain about the Aetna business with a medical benefit ratio of 94.8%. Risks persist, including rising healthcare costs. Future opportunities aim for adjusted EPS of $5.75-$6.00 in 2025, supported by increased investment in integrated capabilities and technology. 🌟📈 Check details in valueverge.com/CVS.